Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:11:36 2024-04-19 am EDT			5-day change	1st Jan Change
5.01 ^USD	-0.60%		-11.64%	+36.33%

Mar. 21	Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC	CI
Mar. 19	Fate Therapeutics Prices $100 Million Offering, Private Placement	MT

Fate Therapeutics, Inc. Expects to Terminate Mark Plavsic as Chief Technical Officer, Effective as of March 6, 2023

January 05, 2023 at 05:05 pm EST

Fate Therapeutics, Inc. announced that in connection with the company's restructuring plan and reduction to its workforce, the employment of Mark Plavsic, Ph.D., D.V.M., the Company's Chief Technical Officer, is expected to terminate effective as of March 6, 2023.

Latest news about Fate Therapeutics, Inc.

Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC	Mar. 20	CI
Fate Therapeutics Prices $100 Million Offering, Private Placement	Mar. 19	MT
Fate Therapeutics, Inc. announced that it expects to receive $19.996366 million in funding from Redmile Group, LLC	Mar. 18	CI
Fate Therapeutics, Inc.(NasdaqGM:FATE) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
Transcript : Fate Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 11:15 AM	Mar. 12
Morgan Stanley Raises Fate Therapeutics Price Target to $7 From $3, Maintains Equalweight Rating	Feb. 27	MT
BMO Capital Adjusts Price Target on Fate Therapeutics to $7 From $6, Maintains Market Perform Rating	Feb. 27	MT
Barclays Adjusts Price Target on Fate Therapeutics to $10 From $6, Maintains Overweight Rating	Feb. 27	MT
Wedbush Raises Fate Therapeutics' Price Target to $7 From $3, Keeps Neutral Rating	Feb. 27	MT
Transcript : Fate Therapeutics, Inc., Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Earnings Flash (FATE) FATE THERAPEUTICS Posts Q4 Revenue $1.7M, vs. Street Est of $1.5M	Feb. 26	MT
Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
Fate Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors	Jan. 08	CI
Fate Therapeutics, Inc.(NasdaqGM:FATE) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Mizuho Lowers Price Target on Fate Therapeutics to $8 From $12, Maintains Buy Rating	Nov. 20	MT
Morgan Stanley Adjusts Price Target on Fate Therapeutics to $3 From $5, Maintains Equalweight Rating	Nov. 13	MT
Wells Fargo Trims Price Target on Fate Therapeutics to $5 From $6, Maintains Equalweight Rating	Nov. 09	MT
Wedbush Lowers Fate Therapeutics' Price Target to $3 From $6, Maintains Neutral Rating	Nov. 09	MT
Transcript : Fate Therapeutics, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Fate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Aura Biosciences Appoints New Chief Medical Officer	23-10-02	MT
Fate Therapeutics, Inc.(NasdaqGM:FATE) dropped from S&P Biotechnology Select Industry Index	23-09-18	CI
Morgan Stanley Adjusts Price Target on Fate Therapeutics to $5 From $8, Keeps Equalweight Rating	23-08-10	MT
Barclays Adjusts Fate Therapeutics Price Target to $6 From $12, Maintains Overweight Rating	23-08-10	MT

Chart Fate Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Companyâs platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Fate Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.04 USD

Average target price

7.8 USD

Spread / Average Target

+54.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FATE THERAPEUTICS, INC.	+36.33%	574M
VERTEX PHARMACEUTICALS INCORPORATED	-2.59%	102B
REGENERON PHARMACEUTICALS, INC.	+3.02%	96.07B
ARGENX SE	-1.31%	21.66B
BIONTECH SE	-18.25%	20.77B
GENMAB A/S	-7.15%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-28.43%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.80%	13.33B
SAREPTA THERAPEUTICS, INC.	+22.03%	10.94B

Bio Therapeutic Drugs